About this trial
In this study, the researchers aim to find a biomarker of PD. Using imaging scans called Positron Emission tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Magnetic Resonance Imaging (MRI). The PET and SPECT scans use small amounts of radiation and specific compounds called tracers, to study chemical changes in the brain in a way not possible with any other procedure. The MRI uses magnetic fields to generate images of brain structure and function
Eligibility criteria
Qualifiers
All subjects must be judged by the investigator able to understand the nature, design, and procedures of the study and must be able to provide a signed and dated informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations.
All subjects must be willing and able to comply with scheduled visits, required study procedures and laboratory tests.
All subjects must be able to travel to the research sites for the study procedures.
Age 25 years or older.
Disqualifiers
Subjects lacking capacity according to investigator's judgment;
Subjects with a clinical diagnosis of dementia as determined by the investigator;
Subjects with current or a recent history of drug or alcohol abuse/dependence;
Current treatment with anticoagulants (e.g. warfarin, heparin) that might preclude the arterial cannulation and the safe completion of the lumbar puncture.
Trial design
Treatments tested in this trial
- Positron Emission Tomography (PET) scan using BU99008 tracer
- FP-CIT Single-photon Emission Computed Tomography (SPECT) scan
- Magnetic Resonance Imaging (MRI) Scan
- Lumbar puncture